Mandate

Vinge advises Active Biotech on rights offering

November 24, 2014

Active Biotech AB (publ) (Nasdaq Stockholm) carries out a rights offering of SEK 225 million. Vinge advises Active Biotech.

The Vinge team primarily consists of Erik Sjöman (partner, capital markets & public M&A) and associates Christian Lindhé, Ludvig Frithiof and Madelene Eriksson.

Related

Vinge has advised Viva Wine Group AB in connection with the acquisition of the Norwegian beverage company Alpha Brands

Vinge has advised Viva Wine Group AB in connection with the acquisition of 60 percent of the shares in the Norwegian beverage company Alpha Brands, for an initial cash purchase price of MNOK 33, with a possible earn-out based on the company's performance development.
February 09, 2026

Vinge advises HAKI Safety AB (publ) in connection with the acquisition of Newbow Aerospace Limited

Newbow Aerospace is a UK-based market-leading manufacturer and supplier of ground support equipment (GSE) used for the safe and efficient maintenance of aircraft.
February 09, 2026

Vinge advises Borgo in connection with its inaugural issuance of primary capital instruments (AT1)

Vinge has advised Borgo AB (publ) in connection with its successful issuance of primary capital instruments (so called “AT1 bonds”) in the amount of SEK 350 million with a floating rate coupon of 3-month STIBOR + 390 basis points.
January 29, 2026